Canada and the European Union (EU) are currently negotiating a comprehensive economic and trade agreement (CETA), which is expected to be concluded by 2012. As part of these negotiations, the EU has tabled proposals that would lengthen the period of market exclusivity for brand-name drugs in Canada by an average of 3.5 years and add nearly $3-billion annually to Canada’s prescription drug bill.

Go to the following link to learn more and send an email telling your MP that you are concerned that Canadian’s health-care money is at risk of being given away to brand-name drug companies based in Europe.

http://www.canadiangenerics.ca/en/news/euProposal.asp

Have you visited CGPA on Facebook and Twitter? 

When you visit our page on Facebook, please visit the “Take Action” tab; here you can find information about the EU’s drug patent proposals under the current trade negotiations with Canada. By clicking on the “Like” button on this tab you will help spread our message about this important issue.